MA28729B1 - Composés et procédés destinés à traiter la dyslipidémie - Google Patents

Composés et procédés destinés à traiter la dyslipidémie

Info

Publication number
MA28729B1
MA28729B1 MA29595A MA29595A MA28729B1 MA 28729 B1 MA28729 B1 MA 28729B1 MA 29595 A MA29595 A MA 29595A MA 29595 A MA29595 A MA 29595A MA 28729 B1 MA28729 B1 MA 28729B1
Authority
MA
Morocco
Prior art keywords
compounds
methods
treating dyslipidemia
dyslipidemia
treating
Prior art date
Application number
MA29595A
Other languages
English (en)
French (fr)
Inventor
Ana Maria Escribano
Maria Carmen Fernandez
Nathan Bryan Mantlo
Ana Isabel Mateo-Herranz
De La Nava Eva Maria Martin
Xiaodong Wang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28729(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA28729B1 publication Critical patent/MA28729B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA29595A 2004-06-24 2006-12-29 Composés et procédés destinés à traiter la dyslipidémie MA28729B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58270804P 2004-06-24 2004-06-24
US62724104P 2004-11-12 2004-11-12
US66486205P 2005-03-24 2005-03-24

Publications (1)

Publication Number Publication Date
MA28729B1 true MA28729B1 (fr) 2007-07-02

Family

ID=35056992

Family Applications (2)

Application Number Title Priority Date Filing Date
MA29595A MA28729B1 (fr) 2004-06-24 2006-12-29 Composés et procédés destinés à traiter la dyslipidémie
MA29596A MA28730B1 (fr) 2004-06-24 2006-12-29 Composes et methodes de traitement de la dyslipidemie

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA29596A MA28730B1 (fr) 2004-06-24 2006-12-29 Composes et methodes de traitement de la dyslipidemie

Country Status (26)

Country Link
US (3) US20080269284A1 (enExample)
EP (3) EP1761521A1 (enExample)
JP (2) JP2008504266A (enExample)
KR (1) KR20070041452A (enExample)
CN (1) CN1972932B (enExample)
AT (1) ATE528304T1 (enExample)
AU (2) AU2005267436A1 (enExample)
BR (2) BRPI0512523A (enExample)
CA (2) CA2570688A1 (enExample)
CR (1) CR8831A (enExample)
CY (1) CY1112124T1 (enExample)
DK (1) DK1761522T3 (enExample)
EA (2) EA200700119A1 (enExample)
EC (2) ECSP067095A (enExample)
ES (1) ES2372291T3 (enExample)
HR (1) HRP20110761T1 (enExample)
IL (2) IL180277A (enExample)
MA (2) MA28729B1 (enExample)
MX (2) MXPA06014716A (enExample)
NO (2) NO20070468L (enExample)
NZ (1) NZ550978A (enExample)
PL (1) PL1761522T3 (enExample)
PT (1) PT1761522E (enExample)
RS (1) RS52064B (enExample)
SI (1) SI1761522T1 (enExample)
WO (2) WO2006012093A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037796A1 (en) * 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
BRPI0508966A (pt) 2004-03-26 2007-08-21 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
US20080269284A1 (en) 2004-06-24 2008-10-30 Eli Lilly And Company Compounds and Methods for Treating Dyslipidemia
WO2007107843A1 (en) * 2006-03-22 2007-09-27 Pfizer Products Inc. Methods of treatment with cetp inhibitors
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2157190B1 (en) 2007-05-17 2017-05-03 EA Pharma Co., Ltd. Method of measuring the activity of lipid-modified enzyme
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN103648495A (zh) 2011-07-08 2014-03-19 诺华股份有限公司 在高甘油三酯对象中治疗动脉粥样硬化的方法
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013187406A1 (ja) * 2012-06-11 2013-12-19 アステラス製薬株式会社 4,4,7-トリフルオロ-1,2,3,4-テトラヒドロ-5h-1-ベンゾアゼピン化合物の製造方法及びその合成中間体
CN103958501B (zh) * 2012-07-16 2016-08-17 上海恒瑞医药有限公司 苯并七元杂环类衍生物、其制备方法及其在医药上的应用
CN119499252A (zh) * 2014-02-05 2025-02-25 新阿姆斯特丹制药私人有限公司 用于治疗或预防心血管疾病的胆固醇酯转移蛋白抑制剂和含所述抑制剂的药物组合物
CN103833637B (zh) * 2014-03-31 2016-01-06 武汉武药制药有限公司 一种制备依塞曲匹（Evacetrapib）中间体的方法
WO2016198908A1 (en) 2015-06-09 2016-12-15 Abbvie Inc. Ror nuclear receptor modulators
JP6549735B2 (ja) 2015-06-09 2019-07-24 アッヴィ・インコーポレイテッド 核内受容体調節剤
BR112021002207A2 (pt) 2018-08-10 2021-05-04 Diapin Therapeutics, Llc tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios
WO2024249901A2 (en) * 2023-06-01 2024-12-05 Nico Therapeutics, Inc. Compounds, compositions, and methods
CN117263810B (zh) * 2023-09-19 2026-01-27 上海凌凯科技股份有限公司 还原硝基苯制备苯胺类化合物以及选择性碘代苯胺类化合物的方法
CN117263966A (zh) * 2023-09-19 2023-12-22 上海凌凯医药科技有限公司 一种硼酸衍生物的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2402506A1 (fr) * 1977-09-09 1979-04-06 Guelennec Emile Le Cisaille pour la decoupe de ferrailles de grandes dimensions
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
CO5271716A1 (es) * 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CA2445623A1 (en) * 2001-04-30 2002-11-07 Pfizer Products Inc. Methods for preparing cetp inhibitors
US7332514B2 (en) 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
PL376156A1 (en) 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
JP2006523218A (ja) 2003-03-04 2006-10-12 高砂香料工業株式会社 光学活性アミン類の製造方法
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
WO2005037796A1 (en) 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
BRPI0508966A (pt) 2004-03-26 2007-08-21 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
US20080269284A1 (en) 2004-06-24 2008-10-30 Eli Lilly And Company Compounds and Methods for Treating Dyslipidemia
US7700774B2 (en) 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸

Also Published As

Publication number Publication date
NZ550978A (en) 2010-08-27
CA2570673A1 (en) 2006-01-05
EP1761522A1 (en) 2007-03-14
EP2479175A1 (en) 2012-07-25
CN1972932A (zh) 2007-05-30
MXPA06014706A (es) 2007-03-12
EP1761522B1 (en) 2011-10-12
EA200700120A1 (ru) 2007-06-29
US20080269284A1 (en) 2008-10-30
JP2008504266A (ja) 2008-02-14
NO20070468L (no) 2007-03-12
ECSP067095A (es) 2007-01-26
CR8831A (es) 2008-11-13
AU2005258241A1 (en) 2006-01-05
IL180277A (en) 2011-08-31
ES2372291T3 (es) 2012-01-18
SI1761522T1 (sl) 2012-02-29
KR20070041452A (ko) 2007-04-18
PT1761522E (pt) 2011-12-21
IL180277A0 (en) 2007-07-04
IL180276A0 (en) 2007-07-04
CY1112124T1 (el) 2015-11-04
US20070244095A1 (en) 2007-10-18
WO2006002342A1 (en) 2006-01-05
ATE528304T1 (de) 2011-10-15
EA012585B1 (ru) 2009-10-30
JP4836945B2 (ja) 2011-12-14
BRPI0512523A (pt) 2008-03-11
ECSP067098A (es) 2007-01-26
EP1761521A1 (en) 2007-03-14
NO20070470L (no) 2007-03-26
US20100204207A1 (en) 2010-08-12
DK1761522T3 (da) 2012-01-02
JP2008504277A (ja) 2008-02-14
MXPA06014716A (es) 2007-03-12
CA2570673C (en) 2013-01-29
HRP20110761T1 (hr) 2011-11-30
CA2570688A1 (en) 2006-02-02
MA28730B1 (fr) 2007-07-02
CN1972932B (zh) 2011-06-29
PL1761522T3 (pl) 2012-03-30
BRPI0512516A (pt) 2008-03-11
AU2005258241B2 (en) 2011-08-25
WO2006012093A1 (en) 2006-02-02
AU2005267436A1 (en) 2006-02-02
EA200700119A1 (ru) 2007-10-26
RS52064B (sr) 2012-06-30
US7786108B2 (en) 2010-08-31
HK1104528A1 (en) 2008-01-18

Similar Documents

Publication Publication Date Title
NO20070470L (no) Sammensetninger og fremgangsmater for behandling av dyslipidemi
DK1817300T3 (da) Forstærkere af glutamat-receptorer
DK1732933T3 (da) Forobindelser til behandling af dyslipidæmi
DK1767535T3 (da) Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse
CY1112311T1 (el) Ενωσεις πυραζολινης ως ανταγωνιστες υποδοχεα αλατοκορτικοειδους
MA28268A1 (fr) Composes et techniques de traitement de la dyslipidemie
EA200602281A1 (ru) Гетероарилсульфоны и сульфонамиды и их терапевтические применения
ATE488510T1 (de) Heterocyclische derivate, deren herstellung und therapeutische verwendung
ATE405544T1 (de) Tyrosinderivate als ppar-gamma-modulatoren